First Tracks Biotherapeutics, Inc. (TRAX)
Market Closed
14 Sep, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary 
XDUS $
37. 57
+1.13
+3.101%
$
1.27B Market Cap
- P/E Ratio
- Div Yield
397,122 Volume
- Eps
$ 36.44
Previous Close Investors:
Want to track TRAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.
Seekingalpha | 4 months ago
